Pharmac News

Pharmac is pleased to let you know that the 2,600+ people currently accessing Lamictal or Arrow-Lamotrigine under the bespoke exceptional circumstances process can remain on their original funded brand.

This process was set up in 2019 following the funded brand change to Logem. They are confident that in that time approvals have been granted for people who were taking lamotrigine at the time of the brand change and needed to stay on their existing brand.

They are therefore closing this process on 1 September 2022 and all current exceptional circumstances approvals will be extended indefinitely.

Pharmac want to make sure that people taking lamotrigine, their whānau, and their healthcare professionals know what’s happening with the brands.

More information is available on:


Lamictal packaging update

Update on Lamictal packaging : please see brand information and video from global GSK team

Lamictal brand of lamotrigine dispersible tablets 25mg, 50mg and 100mg formulations are undergoing package change from a simple blister pack to child-resistant blister packaging.

Lamictal Blister Leave Behind Information Sheet


submissions to pharmac

Epilepsy New Zealand works to ensure New Zealanders living with epilepsy have access to medications necessary for them to live their best lives.  This involves engaging with PHARMAC on a regular basis.

Back to top